fireflyneuro.com (AIFF) - Rasio rega marang prakiraan pendapatan
High costs for FDA certification and patent protection of AI platforms are impacting the growth dynamics of Firefly Neuroscience, Inc (AIFF). The forward P/S ratio reflects the current market capitalization relative to future revenues, with the metric fixed at 7.40. Brand authority among neurologists is increasing due to precise EEG decoding, while unique dementia diagnostic software provides the company with sustainable pricing power within the niche.
Rincian metrik komprehensif lan analitis Firefly Neuro (AIFF)
- rega saham lan target rega konsensus:
- indikator kapitalisasi pasar:
- indikator nilai buku ekuitas:
- indikator total utang lan likuiditas perusahaan:
Utang marang Ekuitas Firefly Neuroscience, Inc|AIFF - Koefisien utang jangka dawa marang modal|Utang jangka cendhak marang ekuitas Firefly Neuroscience, Inc|AIFF - Utang kumulatif perusahaan|Rasio utang marang kapitalisasi buku AIFF|AIFF - Gunggunge utang jangka dawa|Utang jangka cendhak perusahaan Firefly Neuroscience|Rasio cepet fireflyneuro.com
- rincian asil keuangan lan kelipatan valuasi:
AIFF - Asil keuangan resik|Proyeksi bathi mangsa ngarep Firefly Neuroscience, Inc|AIFF - Kapitalisasi marang bathi|Rega marang bathi mangsa ngarep Firefly Neuroscience Inc|AIFF - Rasio P/E diaturake wutah|Pangali EV/EBITDA AIFF|AIFF - Bathi operasional sadurunge ngurangi amortisasi|Bathi resik saben saham (EPS TTM) Firefly Neuroscience|AIFF - Bathi resik saben siji saham sajrone rolas wulan pungkasan|Wutah bathi resik saben saham taun-ka-taun sajrone 12 wulan pungkasan fireflyneuro.com|AIFF - Tambahing bathi saben saham ing taun lumaku|Prakiraan wutah bathi kanggo taun ngarep Firefly Neuroscience, Inc
- rincian pendapatan lan dodolan:
Analisis wiwitan perusahaan:AIFF (Firefly Neuroscience)
To identify fundamental leaders, the analyst evaluates the ratio of market capitalization to expected annual revenue, which determines the premium paid for future growth. The projected P/S metric reflects market expectations for the commercialization of AI-driven brain activity diagnostics by Firefly Neuroscience, Inc (AIFF), helping investors align the share price with the potential for integrating objective neurobiological data into clinical practice.
Analisis perusahaan pesaing
Biogen - Multiplikator forward rega marang pendapatan|Rega forward marang dodolan NBIX|RGC - Rasio rega marang prakiraan pendapatan|AXSM (Axsome Corp) - Kapitalisasi marang prakiraan pendapatan|ACAD: Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep xenon-pharma.com (XENE)|Multiplikator forward rega marang pendapatan VKTX|Multiplikator Forward P/S Supernus Pharmaceuticals, Inc.|Rasio rega marang prakiraan pendapatan Catalyst Pharmaceuticals Inc (CPRX)|DNLI (Denali Corp) - Rega forward marang dodolan|Rasio rega marang prakiraan pendapatan Harmony Biosciences HRMY|biohavenpharma.com (BHVN) - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|AMLX - Rasio rega marang prakiraan pendapatan|Rasio kapitalisasi marang dodolan sing dikarepake Trevi Therapeutics Inc TRVI|PRAX: Multiplikator Forward P/S|Multiplikator forward rega marang pendapatan Anavex Life Sciences Corp|CBLL (CeriBell, Inc.) - Multiplikator Forward P/S|Prothena Corporation (PRTA) - Rasio kapitalisasi marang dodolan sing dikarepake|Multiplikator Forward P/S ALEC|ANNX - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|Rasio rega marang prakiraan pendapatan Omeros OMER|NGNE: Kapitalisasi marang prakiraan pendapatan|AC Immune - Multiplikator Forward P/S|voyagertherapeutics.com (VYGR) - Multiplikator forward rega marang pendapatan|NMRA: Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Scilex Holding (SCLX)|Multiplikator forward rega marang pendapatan TVGN|ACOG: Rega forward marang dodolan|Multiplikator Forward P/S CGTX|Rasio kapitalisasi marang dodolan sing dikarepake inhibikase.com|Rasio rega marang prakiraan pendapatan Cassava Sciences SAVA|ASRT: Kapitalisasi marang prakiraan pendapatan|Coya - Multiplikator Forward P/S|Vistagen Therapeutics (VTGN) - Multiplikator forward rega marang pendapatan|OVID: Multiplikator Forward P/S|acumenpharm.com (ABOS) - Multiplikator Forward P/S|CRVO (CervoMed) - Multiplikator Forward P/S|Alterity Therapeutics Ltd (ATHE) - Rasio kapitalisasi marang dodolan sing dikarepake|Multiplikator Forward P/S CLNN|PEPG: Rega mangsa ngarep marang pendapatan|Multiplikator Forward P/S JUNS (Jupiter Neurosciences Inc)|RLMD (relmada.com) - Rega mangsa ngarep marang pendapatan|ANVS - Rasio rega marang prakiraan pendapatan|GRCE (Grace Therapeutics, Inc.) - Kapitalisasi marang prakiraan pendapatan|KLTO: Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep NeuroSense Therapeutics Ltd. (NRSN)|Multiplikator forward rega marang pendapatan RVPH|Multiplikator Forward P/S MetaVia, Inc.|Rasio rega marang prakiraan pendapatan NeurAxis (NRXS)|HSDT (heliusmedical.com) - Rega forward marang dodolan|Rasio rega marang prakiraan pendapatan Passage Bio PASG|Neuphoria Therapeutics, Inc. (NEUP) - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|Minerva Neurosciences - Multiplikator Forward P/S|Rega mangsa ngarep marang pendapatan ATHA|ADXN: Multiplikator Forward P/S|ALZN - Rasio kapitalisasi marang dodolan sing dikarepake|Rasio rega marang prakiraan pendapatan Cyclerion Therapeutics Inc.|PTIX: Rega forward marang dodolan|Multiplikator Forward P/S KTTA|CRGT - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|Multiplikator Forward P/S ATXI (Avenue Therapeutics, Inc.)|BCLI (Brainstorm Cell Therapeutics Inc.) - Rega mangsa ngarep marang pendapatan|CARA - Rasio rega marang prakiraan pendapatan|CHRO: Rasio rega marang prakiraan pendapatan|ELYM (eliemtx.com) - Multiplikator forward rega marang pendapatan|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Intra-Cellular Therapies, Inc. (ITCI)|Multiplikator forward rega marang pendapatan LBPH|MRNS: Rega forward marang dodolan|Rasio rega marang prakiraan pendapatan NKGen (NKGN)|NeuroBo Pharma - Kapitalisasi marang prakiraan pendapatan|Multiplikator Forward P/S SAGE (Sage Therapeutics, Inc.)|synaptogen.com (SNPX) - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|TRVN: Multiplikator forward rega marang pendapatan|VIGL - Multiplikator Forward P/S|Anew Medical (WENA) - Rasio rega marang prakiraan pendapatan|Cerevel Corp - Rega forward marang dodolan
